@article {1964, title = {Effect of Butionin-Sulfaximine and Fluphenazine as Trypanothione Inhibitory Drugs on Promastigotes and Axenic Amastigotes of Leishmania Peruviana and Leishmania Braziliensis}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {March 2023}, pages = {82-85}, type = {Original Article }, chapter = {82}, abstract = {

Background: Leishmaniasis is a disease caused by the Leishmania parasite, which is difficult to diagnose, causes disfigurement and is difficult to treat. Objectives: To determine the effect of Butionin-Sulfaximine (BSO) and Fluphenazine on trypomastigotes and axenic amastigotes of Leishmania peruviana and Leishmania braziliensis. Methods: A study was performed with Butionin-Sulfaximine (BSO), Fluphenazine, and Glucantime (positive control,) utilizing respective concentrations of 41.7 mg/ml, 4.17 mg/ml, and 50 mg/ml for twenty-four hours on axenic amastigotes. Results: A significant difference (*P \< 0.05) was found between the negative control group, Fluphenazine, and BSO within both the axenic amastigotes of L. peruviana (5.5 X 105 / ml for the negative control, 0.15 X 105 / ml for Fluphenazine, and 0.7 X 105 / ml for BSO) and L. braziliensis (6.9 X 105/ml for the negative control, 0.18 X 105/ml for Fluphenazine, and 0.22 X 105/ml for BSO). Another significant difference (*P \< 0.05) was found in the promastigotes of L. peruviana (5.9 X 105 / ml for the negative control, 0.66 X 105 / ml for Fluphenazine, and 3.1 X 105 / ml for BSO) and L. braziliensis (8.7 X 105/ml for the negative control and 5.68 X 105/ml for Fluphenazine). Conclusions: From this, we conclude Fluphenazine and BSO present promising antiparasitic effects against axenic amastigotes of L. peruviana and L. braziliensis in both pharmacological tests of the in vivo model and their potential future use.

}, keywords = {Axenic Amastigote, Butionin-Sulfaximine, Fluphenazine, Leishmania}, doi = {10.5530/pj.2023.15.11}, author = {Jes{\'u}s Rojas-Jaimes and Marco Mes{\'\i}a-Guevara and Alexander Murillo-Zenozain} } @article {2139, title = {Generation of Multinucleated Giant Cells due to Leishmania (V.) braziliensis Infection}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {October 2023}, pages = {905-909}, type = {Research Article}, chapter = {905}, abstract = {

Background: Multinucleated giant cells were first described by Langhans(MGCs), these MGCs have a role in innate immunity that includes extracellular matrix remodeling associated with granuloma formation; another function of them is to participate in the removal of cellular debris in apoptosis during certain infections. Objective: Generate multinucleated giant cells due to Leishmania (V.) braziliensis infection. Methods: For infection macrophage/parasite ratio of 1 to 10 using the RAW 264.7-line (5 x105/mL) and Leishmania (V.) braziliensis metacyclic promastigotes (50 x105/mL) was a strain maintained in culture Schneider liquid medium, supplemented with 20\% fetal bovine serum and 10 000 U/10 mg/mL penicillin streptomycin at pH 7 and 25 {\textdegree}C in the laboratory. Incubation was continued for 4 days, and microscopic observation at 1000X was performed at 24 hours and 96 hours, respectively. Results: In our study an MGC conversion was observed at 96 hours (50\% {\textpm} 28.2). Conclusions: In vitro MGC model could be used to study the physiopathology of MGC generation by Leishmania (V.) braziliensis infection.

}, keywords = {Immunity, Infection, Leishmania (V.) braziliensis, Macrophage, Multinucleated Giant Cells}, doi = {10.5530/pj.2023.15.172}, author = {Jes{\'u}s Rojas-Jaimes and Luis Casta{\~n}eda Pelaez} } @article {1937, title = {Antiparasitic effect of Psidium guajava on promastigotes and axenic amastigotes of Leishmania}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {January 2023}, pages = {973-977}, type = {Research Article }, chapter = {973-977}, abstract = {

Background: Leishmaniasis is a stigmatic and mutilating disease due to pathogenic species of the genus Leishmania which, depending on the species and the individual{\textquoteright}s immune status, may vary clinically from a cutaneous, mucosal, and visceral form, and for which there is no suitable treatment without significant side effects. Objectives: To measure the effect of ethanolic and aqueous extracts of Psidium guajava against axenic promastigotes and amastigotes of Leishmania spp. Methods: The method of [3- (3,4 -dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide] was used to study the antiparasitic effects of ethanolic (100mg/mL) and aqueous (100mg/mL) extracts of Psidium guajava on axenic amastigotes cultures (8.1 x103 parasite/mL) and promastigotes (12 x 104 parasite/mL) obtained from a patient with cutaneous\ leishmaniasis, and the percentage of parasite death was evaluated in comparison with Glucantime (300mg/mL) and untreated parasite cultures. Results: Regarding parasite death in promastigotes, the ethanolic and aqueous extracts had a percentage of 22.58\% and -45.16\%, respectively, with no significant difference between treatments (N=3) (p= 0.058). In contrast, the ethanolic and aqueous extracts had an antiparasitic percentage of 91.67\% and -70.83\%, respectively, with a significant difference between treatments (N=3) (p\<0.05). Conclusions: Our study showed high and significant effectiveness in parasite death (91.67\%) of Leishmania axenic amastigotes of the ethanolic extract (100mg/mL) of Psidium guajava, being this result promising and the basis for in vivo studies, using the ethanolic extraction of P. guajava

}, keywords = {Amastigote, Leishmania, Promastigote, Psidium guajava}, doi = {10.5530/pj.2022.14.198}, author = {Jes{\'u}s Rojas-Jaimes and Marco Mes{\'\i}a-Guevara and Maria Rojas-Puell and Luis Casta{\~n}eda- Pelaez} }